Bristol-Myers Squibb Company Common Stock (BMY)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 19, 2026Investment Snapshot
- Trading 87% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 43.1% with 18.3% net margin
- High dividend yield of 4.3%
Bristol-Myers Squibb Company Common Stock (BMY) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $117.0 billion . Key value metrics: P/E ratio 13.5, P/B ratio 5.83, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Bristol-Myers Squibb Company Common Stock — Fundamental Analysis Summary
Bristol-Myers Squibb Company Common Stock (BMY) is currently trading 87% above its Graham Number of $30.59, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 13.5x.
On financial health, BMY shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 43.1% (sector average: -20.6%), and high leverage with a debt-to-equity ratio of 2.31.
StockPik's composite Value Score for BMY is 76/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BMY shows revenue declining at 0% year-over-year, with earnings growing at 179%.
BMY pays a solid dividend yield of 4.3%.